Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Assertio Holdings Inc.

The latest update is out from Assertio Therapeutics ( ($ASRT) ). On November 17, 2025, Brendan P. O’Grady, former CEO of Assertio Holdings, Inc., e...

Assertio Therapeutics Announces Leadership Change with CEO Resignation

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Assertio Therapeutics today and set a price target of $3.00. Selvaraju covers the ...

Market Cap	$74.10M	P/E Ratio	N/A
52W High	$1.08	52W Low	$0.51
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-97.2%	52W Position	36.7%
Overall Score	46	Value Score	60
Quality Score	--	Technical Score	33

EPS Current Est	$-0.44	EPS Next Est	$-0.02
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASRT	$0.72	-0.80%	404.58K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASRT	$0.72	-0.8%	404.58K
3
4
5
6

ASRT

ASRT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Assertio Holdings Inc. Data in Excel

Get Assertio Holdings Inc. Data in Excel